Xofluza 40 Mg Dose Pack Shortage: A Provider Briefing for 2026

For providers prescribing Xofluza 40 Mg Dose Pack (Baloxavir Marboxil) during the 2025-2026 flu season, availability challenges remain a recurring concern. This briefing covers the current shortage status, prescribing implications, cost and access considerations, and actionable tools to help your patients locate this medication.

Current Shortage Status

As of early 2026, Baloxavir Marboxil is not listed on the FDA Drug Shortage Database. However, real-world availability at the retail pharmacy level continues to be inconsistent during peak influenza season. This pattern has been observed in consecutive flu seasons since 2022-2023.

The core issue is not a manufacturing shortage but rather a distribution and stocking gap. Genentech continues to manufacture Xofluza, but the drug's seasonal demand profile, single-dose format, and brand-only status create predictable access challenges for patients at the point of dispensing.

Timeline of Availability Issues

Understanding the pattern helps with prescribing decisions:

• 2022-2023 flu season — Early and severe flu season led to widespread reports of Xofluza stockouts at retail pharmacies nationwide
• 2023-2024 flu season — Moderate season with fewer availability complaints, though spot shortages persisted in high-demand areas
• 2024-2025 flu season — Severe season with significant access challenges from November 2024 through February 2025
• 2025-2026 flu season — Availability issues have again been reported during the January-February peak, particularly at chain pharmacy locations

Prescribing Implications

Weight-Based Dosing

Xofluza dosing is weight-based, which requires accurate patient weight at the time of prescribing:

• 20 kg to <40 kg: 20 mg single dose
• 40 kg to <80 kg: 40 mg single dose (the 40 Mg Dose Pack)
• ≥80 kg: 80 mg single dose (two 40 mg tablets)

The 40 mg dose pack is the most commonly prescribed formulation. For patients weighing ≥80 kg, ensure the prescription specifies two 40 mg tablets or an 80 mg dose to avoid dispensing errors.

Time-Sensitive Administration

Baloxavir must be administered within 48 hours of symptom onset for treatment efficacy. This narrow therapeutic window makes availability especially critical — a 24-48 hour delay in locating the medication can render the prescription clinically moot.

Drug Interaction Considerations

Counsel patients and verify medication lists for polyvalent cation interactions. Calcium, iron, magnesium, selenium, and zinc supplements — as well as dairy products and antacids — significantly reduce Baloxavir plasma concentrations. For comprehensive interaction data, see: Xofluza Drug Interactions: What to Avoid.

Additionally, Xofluza may interfere with the live attenuated influenza vaccine (LAIV). Avoid prescribing Xofluza within 2 weeks before or 48 hours after LAIV administration.

The Availability Picture

Several structural factors contribute to Xofluza's availability challenges:

• No generic competition — Baloxavir Marboxil remains under patent protection with no approved generics as of 2026
• Single manufacturer — Genentech (Roche) is the sole producer, creating a single-pipeline supply dependency
• Seasonal demand — Unlike chronic-use medications, Xofluza demand is concentrated in a 4-5 month window
• Pharmacy stocking economics — At $150-$200 per dose pack wholesale, pharmacies face financial risk stocking a seasonal, single-dose product with an uncertain sell-through rate
• Chain pharmacy allocation models — Large chains may allocate limited quantities per location, which depletes rapidly during local flu surges

Cost and Access Considerations

Patient Cost Burden

• Cash price: $150-$200 per 40 mg dose pack
• Insured patients: Copay varies; some plans require prior authorization or step therapy (typically requiring trial of Oseltamivir first)
• Genentech savings card: Reduces copay to as low as $30 for commercially insured patients
• Genentech Patient Foundation: Provides Xofluza at no cost for eligible uninsured/underinsured patients

Prior Authorization and Step Therapy

Be aware that many commercial and Medicare Part D plans have implemented step therapy requirements for Xofluza, requiring documentation that Oseltamivir is unavailable, contraindicated, or previously failed before covering Baloxavir. Given the 48-hour treatment window, this can be a significant barrier.

Consider including clinical justification in your prescription notes (e.g., patient adherence concerns with 5-day regimen, Oseltamivir intolerance) to expedite prior authorization when possible.

Tools and Resources for Providers

Medfinder for Providers

Medfinder offers real-time pharmacy availability data that can be integrated into your prescribing workflow. Before sending a prescription to a specific pharmacy, you can verify stock availability to reduce patient callbacks and prescription transfer delays.

Visit medfinder.com/providers for provider-specific tools and resources.

Prescribing Workflow Optimization

1. Verify pharmacy stock before transmitting the prescription — use Medfinder or call the dispensing pharmacy directly
2. Prepare an alternative — have an Oseltamivir prescription ready as a backup if Xofluza cannot be located
3. Inform patients about the savings card — many patients abandon prescriptions due to cost; the Genentech savings card significantly reduces copays
4. Document the 48-hour window — note symptom onset time in the chart to support urgent dispensing and prior authorization requests

Alternative Antivirals

When Xofluza is unavailable, the following alternatives should be considered:

• Oseltamivir (Tamiflu) — 75 mg BID x 5 days; generic available; most widely stocked antiviral; $20-$50 with discount card
• Zanamivir (Relenza) — 10 mg (2 inhalations) BID x 5 days; contraindicated in patients with reactive airway disease
• Peramivir (Rapivab) — 600 mg single IV dose; useful for patients who cannot take oral medications or in inpatient settings

For a patient-facing comparison: Alternatives to Xofluza.

Looking Ahead

No generic Baloxavir applications have been approved, and none are anticipated in the near term. The seasonal availability pattern is likely to continue for the foreseeable future. Providers should build Xofluza availability verification into their flu-season prescribing workflows and maintain familiarity with alternative regimens.

Pipeline antiviral candidates in the cap-dependent endonuclease inhibitor class may eventually provide additional options, but none have reached late-stage clinical trials as of early 2026.

Final Thoughts

Xofluza remains a valuable single-dose option for influenza treatment and prophylaxis, but real-world availability continues to lag behind prescribing demand during peak flu season. By verifying pharmacy stock before prescribing, maintaining alternative prescriptions, and directing patients to tools like Medfinder, providers can minimize disruptions to patient care.

For additional provider resources, visit medfinder.com/providers.